mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar
Author | Chemaitelly, Hiam |
Author | Yassine, Hadi M. |
Author | Benslimane, Fatiha M. |
Author | Al Khatib, Hebah A. |
Author | Tang, Patrick |
Author | Hasan, Mohammad R. |
Author | Malek, Joel A. |
Author | Coyle, Peter |
Author | Ayoub, Houssein H. |
Author | Al Kanaani, Zaina |
Author | Al Kuwari, Einas |
Author | Jeremijenko, Andrew |
Author | Kaleeckal, Anvar Hassan |
Author | Latif, Ali Nizar |
Author | Shaik, Riyazuddin Mohammad |
Author | Abdul Rahim, Hanan F. |
Author | Nasrallah, Gheyath K. |
Author | Al Kuwari, Mohamed Ghaith |
Author | Al Romaihi, Hamad Eid |
Author | Al-Thani, Mohamed H. |
Author | Al Khal, Abdullatif |
Author | Butt, Adeel A. |
Author | Bertollini, Roberto |
Author | Abu-Raddad, Laith J. |
Available date | 2021-10-20T07:59:40Z |
Publication Date | 2021-09-01 |
Publication Name | Nature Medicine |
Identifier | http://dx.doi.org/10.1038/s41591-021-01446-y |
Citation | Chemaitelly, H., Yassine, H.M., Benslimane, F.M. et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med 27, 1614–1621 (2021). https://doi.org/10.1038/s41591-021-01446-y |
ISSN | 10788956 |
Abstract | The SARS-CoV-2 pandemic continues to be a global health concern. The mRNA-1273 (Moderna) vaccine was reported to have an efficacy of 94.1% at preventing symptomatic COVID-19 due to infection with ‘wild-type’ variants in a randomized clinical trial. Here, we assess the real-world effectiveness of this vaccine against SARS-CoV-2 variants of concern, specifically B.1.1.7 (Alpha) and B.1.351 (Beta), in Qatar, a population that comprises mainly working-age adults, using a matched test-negative, case-control study design. We show that vaccine effectiveness was negligible for 2 weeks after the first dose, but increased rapidly in the third and fourth weeks immediately before administration of a second dose. Effectiveness against B.1.1.7 infection was 88.1% (95% confidence interval (CI): 83.7–91.5%) ≥14 days after the first dose but before the second dose, and was 100% (95% CI: 91.8–100.0%) ≥14 days after the second dose. Analogous effectiveness against B.1.351 infection was 61.3% after the first dose (95% CI: 56.5–65.5%) and 96.4% after the second dose (95% CI: 91.9–98.7%). Effectiveness against any severe, critical or fatal COVID-19 disease due to any SARS-CoV-2 infection (predominantly B.1.1.7 and B.1.351) was 81.6% (95% CI: 71.0–88.8%) and 95.7% (95% CI: 73.4–99.9%) after the first and second dose, respectively. The mRNA-1273 vaccine is highly effective against B.1.1.7 and B.1.351 infections, whether symptomatic or asymptomatic, and against any COVID-19 hospitalization and death, even after a single dose. |
Language | en |
Subject | Epidemiology RNA vaccines Viral infection |
Type | Article |
Pagination | 1614-1621 |
Issue Number | 9 |
Volume Number | 27 |
ESSN | 1546-170X |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |
This item appears in the following Collection(s)
-
Biomedical Research Center Research [709 items ]
-
Biomedical Sciences [692 items ]
-
COVID-19 Research [799 items ]
-
Mathematics, Statistics & Physics [722 items ]
-
Public Health [401 items ]